Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedResults for NCT03222856 have been posted, including efficacy and safety outcomes. The study record now shows updated completion and enrollment dates.SummaryDifference0.4%

- Check21 days agoNo Change Detected
- Check42 days agoChange DetectedUpgrade to v3.2.0 with a prominent operating-status notice and links; v3.1.0 is removed.SummaryDifference2%

- Check49 days agoChange DetectedUpdate versioning from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision bumped to v3.0.2; 'Back to Top' link removed.SummaryDifference0.1%

- Check71 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check78 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations related to breast cancer treatment, while also removing previous references to certain locations and medical terms.SummaryDifference2%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.